lactobacillus johnsonii n6.2

Lactobacillus johnsonii N6.2 is a specific probiotic bacterial strain within the Lactobacillaceae family, originally characterized by Fujisawa et al., 1992[6]. It is a live biotherapeutic product and has been studied for its health-promoting properties in both animal models and humans[1][8]. Mechanistically, L. johnsonii N6.2 exerts immunomodulatory effects by modulating the assembly of the inflammasome (evidenced by reduced caspase-1 activation), producing metabolites such as hydrogen peroxide that inhibit pro-inflammatory pathways (notably indoleamine 2,3-dioxygenase/IDO), and influencing gut microbiota composition[1][2][8]. The strain synthesizes cinnamoyl esterases to enhance absorption of bioactive phytophenols and can utilize dietary fatty acids like erucic acid to generate health-relevant long-chain fatty acids[1][8]. In preclinical studies, it has shown benefits in reducing gastrointestinal inflammation, improving metabolic syndrome biomarkers, and mitigating onset of type 1 diabetes in animal models; these effects have been partially reproduced in human subjects[1][4][8]. Clinical trials are ongoing to evaluate its safety and efficacy as an adjunctive therapy for type 1 diabetes mellitus (T1D)[4].

Other names

lactobacillus johnsonii strain n6.2l. johnsonii n6.2